Veracyte Prices IPO, Targets $65M in Gross Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte today priced its initial public offering of 5 million shares at $13 per share.

The South San Francisco, Calif.-based firm is expected to begin trading today on the Nasdaq Global Market under the symbol "VCYT." It will realize gross proceeds of $65 million from the offering, though the underwriters of the IPO have a 30-day option to purchase 750,000 additional shares to cover any over-allotments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.